# Taysha Gene Therapies share price today (Taysha Gene Therapies, Inc., TSHA)

> Taysha Gene Therapies, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. TSHA · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/tsha

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $4.09 (+6.8% in a year)
- Revenue (Dec 2025): $5.5 M (+171.3% on a year ago)
- Profit (Dec 2025), incl. one-off: −$27.9 M (one-off item, see below)
- ROE: −44%, FY25

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Taysha Gene Therapies share price today? Taysha Gene Therapies, Inc.'s share price was $4.09 at the close on 5 November 2026. It has been moving sideways for 9 weeks. That is 23.0% below its average price over the last 200 trading days. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 11 weeks running. In the last 52 weeks it traded between $4 and $7, and at that close it sat 15% of the way up from that low. Over the last 6.1 years the share price moved −83% while the S&P 500 moved +123%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 21 August 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Taysha Gene Therapies pay? Taysha Gene Therapies, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Taysha Gene Therapies on? Taysha Gene Therapies is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Taysha Gene Therapies profitable? Taysha Gene Therapies, Inc. posted a net loss of $27.9 M in the Dec 2025 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of $109 M. That loss is 507.8% of the quarter's revenue. The same quarter a year earlier lost $25.5 M. 11 of the last 12 reported quarters were loss-making. Read this profit with care: at −$27.9 M it is bigger than the quarter's whole revenue of $5.5 M. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −516.0% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does Taysha Gene Therapies make, and is it growing? Taysha Gene Therapies, Inc. reported $5.5 M of revenue in the Dec 2025 quarter, +171.3% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 3 years it has grown 57.5% a year on average. The last full year, FY25, came in at $9.8 M. FY25 revenue was $9.8 M, +17.3% on the year before. Recent pace: the last four quarters grew +43.4% on average, against 57.5% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +19.0%, against −9.3% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does Taysha Gene Therapies keep? Taysha Gene Therapies, Inc. has almost no sales yet: FY25 revenue was $9.8 M. On sales that small an operating margin is not a useful reading, so this section is left out until sales grow. ## Is Taysha Gene Therapies' profit turning into cash? Taysha Gene Therapies, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $93.1 M of cash, against −$109 M of profit. After $738 K of spending on assets, free cash was −$93.8 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Taysha Gene Therapies' cash go? Taysha Gene Therapies, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $5.0 M on assets over the last 3 years. Averaged over those years that is 17.0% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $5.0 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Taysha Gene Therapies' P/E ratio, and how does it compare with its own history? Taysha Gene Therapies, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Taysha Gene Therapies, Inc. at 136.4× its FY25 revenue of $9.8 M. The P/E comes back here once profit turns positive. ## Is the Taysha Gene Therapies business getting better or worse? Taysha Gene Therapies, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 8 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Taysha Gene Therapies earn on its capital? Taysha Gene Therapies, Inc. earned a ROE of −44% in FY25. That is up from a low of −17,494% in FY22. Its return on capital used (ROIC) is left out: on sales this small it reads −25%, a number that says nothing useful about the business. ## Does Taysha Gene Therapies have too much debt? Taysha Gene Therapies, Inc. has total debt of $56.7 M against shareholder equity of $387 M as of Jun 2026, so its debt is 0.15× its equity, which is very little. Year by year, that ratio went from 0.66 in FY21 to 0.28 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Taysha Gene Therapies shareholding pattern? 22.0% of Taysha Gene Therapies, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 10.8 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Taysha Gene Therapies from balance-sheet trouble? For Taysha Gene Therapies, Inc., the Z-score is 6.81. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 6.81 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Taysha Gene Therapies rank in its industry? There is no score against its industry: Taysha Gene Therapies, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Taysha Gene Therapies compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Taysha Gene Therapies in size? Taysha Gene Therapies is the 100th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Ocular Therapeutix, Inc., Innoviva, Inc. and AnaptysBio, Inc. Just below it: UroGen Pharma, Nektar Therapeutics and MannKind Corporation. ### Biotechnology companies close in size

1. [Ocular Therapeutix, Inc.](https://www.sectoralpha.in/us/stocks/ocul) $1.4 billion
2. [Innoviva, Inc.](https://www.sectoralpha.in/us/stocks/inva) $1.4 billion
3. [AnaptysBio, Inc.](https://www.sectoralpha.in/us/stocks/anab) $1.4 billion
4. Taysha Gene Therapies, Inc. $1.3 billion
5. [UroGen Pharma Ltd.](https://www.sectoralpha.in/us/stocks/urgn) $1.3 billion
6. [Nektar Therapeutics](https://www.sectoralpha.in/us/stocks/nktr) $1.2 billion
7. [MannKind Corporation](https://www.sectoralpha.in/us/stocks/mnkd) $1.2 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Empire State Realty OP, L.P.](https://www.sectoralpha.in/us/stocks/esba) $1.4 billion · REIT - Office
2. [G-III Apparel Group, Ltd.](https://www.sectoralpha.in/us/stocks/giii) $1.4 billion · Apparel Manufacturing
3. Taysha Gene Therapies, Inc. $1.4 billion
4. [Revolve Group, Inc.](https://www.sectoralpha.in/us/stocks/rvlv) $1.4 billion · Internet Retail
5. [AnaptysBio, Inc.](https://www.sectoralpha.in/us/stocks/anab) $1.4 billion · Biotechnology

## What else do people ask about Taysha Gene Therapies? ### What were Taysha Gene Therapies's latest quarterly results? Taysha Gene Therapies, Inc. reported revenue of $5.5 M and a net loss of $27.9 M for the Dec 2025 quarter. Earnings per share were −$0.08. The operating margin was −516.0%, 469.8 percentage points higher than a year earlier (as of 5 November 2026). ### What is Taysha Gene Therapies's market cap? Taysha Gene Therapies, Inc.'s market capitalisation is $1.3 B at a stock price of $4.09. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Taysha Gene Therapies performing? Taysha Gene Therapies, Inc.'s share price has been moving sideways for 9 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 11 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Taysha Gene Therapies's stock price go up? This page does not forecast Taysha Gene Therapies, Inc.'s stock price. What it shows instead: the stock price is $4.09, and it has been moving sideways for 9 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### What could break the Taysha Gene Therapies story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Taysha Gene Therapies a stock worth studying right now? What the numbers show: Taysha Gene Therapies, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.